FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2940582157> ?p ?o ?g. }

• W2940582157 endingPage "689" @default.
• W2940582157 startingPage "688" @default.
• W2940582157 abstract "To the Editor: We read with great interest the meta-analysis by Shapiro et al. (1) regarding the outcomes of primary radiosurgery (RS) for glomus jugulare treatment. First, we would like to remark that the pathological entity should be referred to using its appropriate designation: “glomus” is a misnomer, the use of which has been criticized by eminent authors. Rather, it should be designated “tympanojugular paraganglioma” (TJP). It is interesting that only 15 full-text studies regarding RS in TJP met the revised criteria for inclusion in this meta-analysis (out of 959 studies, practically 1.5%) (1). From the initial review, only 2 studies (out of 959, 0.2%) met initial inclusion/exclusion criteria. This means that over 98% of the literature regarding the efficacy of RS in TJP does not show any evidence of scientific and clinical impact. Overall, only 91 TJP patients were analyzed in terms of pre and post-treatment symptoms, tumor control, complications, and follow-up. Focusing on Table 1 of Shapiro's et al. article (“included studies and study characteristics”), from the 15 studies that met the criteria for meta-analysis, only 6 (40%) reported data on tumor size change after treatment, and this with different criteria for each study. This means that 60% of the selected studies did not report any criterion to assess tumor changes after treatment. Therefore, the rate of tumor control is likely overestimated. Moreover, none of the considered studies reported a wait and scan (W&S) protocol before RS. Focusing on Table 2 (“individual patient characteristics”), individual data on 72 patients out of 91 have been reported. Excluding 12 patients with no mention on follow-up, only 60 cases were properly screened after treatment. 37 cases (62%) had a follow-up ≤ 36 months (64% of which with a follow-up ≤ 24 mo); 17 cases (28%) had a follow-up between 37 and 60 months; 6 cases (10%) had a follow-up > 60 months. A total of 54 patients (90%) had a follow-up ≤ 60 months. In a previous study (2) we managed 47 patients with class C & D TJP only with W&S, demonstrating that 92% of the tumors remained stable or showed regression with a follow-up of less than 36 months. In a second group of patients with 36 to 60 months follow-up, tumor stability or regression was observed in 83%. So, which is the real effectiveness of RS in terms of tumor control, considering the indolent natural history of the tumor? All the six cases with a follow-up > 60 months showed tumor control after RS. However, four of these six patients were included in studies where no criteria for tumor size change were reported. We showed that with W&S alone tumor stability or regression can be observed in 45% of the patients with follow-up > 60 months (2). Further concerns regard tumor classification. Of the 72 patients reported in Table 2, 31 (43%) had no annotations regarding tumor classification. These patients and the relative papers should be removed from the meta-analysis. Considering that for these cases the mean pretreatment volume size was 8.9 cm3 (range 1.6–42.4 cm3), most of them probably were small tumors (possibly even class B tympanomastoid paragangliomas according to Fisch Classification), which can be removed surgically without any significant complication (3). The same is for the four cases reported as Stage I according to the Glasscock-Jackson classification. Presently, there are no indications for management with W&S or RS in Class B tumors (4–6). Similarly, Class C1 and C2 tumors can be removed completely using the infratemporal fossa approach type A with low morbidity (7). Moreover, our ongoing studies on the biology of paraganglioma indicate that these tumors express proteins that confer intrinsic radioresistance and drive the epithelial to mesenchymal transition. This is due to the activation of the NOTCH signaling and ZEB1 expression, which are well-known markers of radioresistance (8,9). Also, some of the microRNAs that we found to be significantly down-regulated in head and neck paragangliomas, such as mir-34b/c and miR-200c (8), are known to enhance radiosensitivity by promoting radiation-induced apoptosis in cancer (9–11). The loss of these microRNAs entails radioresistance in paragangliomas. In conclusion, many of our doubts regarding the real effectiveness of RS in TPJ are confirmed by the drawbacks of the meta-analysis by Shapiro et al. Indeed, when carefully interpreted, the literature data show that RS is far from demonstrating any significant advantage in the management of TJP, both in the short and long terms." @default.
• W2940582157 created "2019-05-03" @default.
• W2940582157 creator A5035289896 @default.
• W2940582157 creator A5051393909 @default.
• W2940582157 creator A5056405634 @default.
• W2940582157 date "2019-06-01" @default.
• W2940582157 modified "2023-09-26" @default.
• W2940582157 title "Are Ouctomes of Radiosurgery for Tympanojugular Paraganglioma Overestimated?" @default.
• W2940582157 cites W1968327747 @default.
• W2940582157 cites W1968640027 @default.
• W2940582157 cites W1983635383 @default.
• W2940582157 cites W1984807634 @default.
• W2940582157 cites W1985768135 @default.
• W2940582157 cites W1997206305 @default.
• W2940582157 cites W2025762055 @default.
• W2940582157 cites W2157869280 @default.
• W2940582157 cites W2782216483 @default.
• W2940582157 cites W2888190381 @default.
• W2940582157 doi "https://doi.org/10.1097/mao.0000000000002221" @default.
• W2940582157 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31083102" @default.
• W2940582157 hasPublicationYear "2019" @default.
• W2940582157 type Work @default.
• W2940582157 sameAs 2940582157 @default.
• W2940582157 citedByCount "4" @default.
• W2940582157 countsByYear W29405821572020 @default.
• W2940582157 countsByYear W29405821572021 @default.
• W2940582157 countsByYear W29405821572022 @default.
• W2940582157 crossrefType "journal-article" @default.
• W2940582157 hasAuthorship W2940582157A5035289896 @default.
• W2940582157 hasAuthorship W2940582157A5051393909 @default.
• W2940582157 hasAuthorship W2940582157A5056405634 @default.
• W2940582157 hasBestOaLocation W29405821571 @default.
• W2940582157 hasConcept C142724271 @default.
• W2940582157 hasConcept C143998085 @default.
• W2940582157 hasConcept C19527891 @default.
• W2940582157 hasConcept C204787440 @default.
• W2940582157 hasConcept C2777596629 @default.
• W2940582157 hasConcept C71924100 @default.
• W2940582157 hasConceptScore W2940582157C142724271 @default.
• W2940582157 hasConceptScore W2940582157C143998085 @default.
• W2940582157 hasConceptScore W2940582157C19527891 @default.
• W2940582157 hasConceptScore W2940582157C204787440 @default.
• W2940582157 hasConceptScore W2940582157C2777596629 @default.
• W2940582157 hasConceptScore W2940582157C71924100 @default.
• W2940582157 hasIssue "5" @default.
• W2940582157 hasLocation W29405821571 @default.
• W2940582157 hasLocation W29405821572 @default.
• W2940582157 hasLocation W29405821573 @default.
• W2940582157 hasOpenAccess W2940582157 @default.
• W2940582157 hasPrimaryLocation W29405821571 @default.
• W2940582157 hasRelatedWork W2035462190 @default.
• W2940582157 hasRelatedWork W2054403964 @default.
• W2940582157 hasRelatedWork W2063270751 @default.
• W2940582157 hasRelatedWork W2390548009 @default.
• W2940582157 hasRelatedWork W2788130263 @default.
• W2940582157 hasRelatedWork W3031100919 @default.
• W2940582157 hasRelatedWork W3138321193 @default.
• W2940582157 hasRelatedWork W3168139085 @default.
• W2940582157 hasRelatedWork W4226108959 @default.
• W2940582157 hasRelatedWork W4283268474 @default.
• W2940582157 hasVolume "40" @default.
• W2940582157 isParatext "false" @default.
• W2940582157 isRetracted "false" @default.
• W2940582157 magId "2940582157" @default.
• W2940582157 workType "article" @default.